



Paris, August 25th 2011 – 5:45pm

Issuance of 7.5 M€ reserved convertible bonds, at the reference price of 12.65 € per share

AB Science SA (NYSE Euronext - FR0010557264- AB), a pharmaceutical company specialised in research, development and commercialisation of protein kinase inhibitors (PKI), reports to have issued a bond loan agreement, convertible or reimbursable in ordinary shares, for the nominal amount of € 7,539,400, with investors who are already shareholders (The “Bonds”).

The Bonds, convertible or reimbursable in ordinary shares, for the nominal amount of € 7,539,400, whose issuance was approved on 23 May 2011 by the general assembly, has been fully subscribed and issued. The Bonds will bear 1.25% interest to be paid annually. They will also bear 4.75% accrued interest to be paid only in case of reimbursement of the loan in cash.

The Bonds will be convertible into shares at any time at the initiative of the Bondholder at the price of 12.65 euros per share. The Bonds may be reimbursed by anticipation in cash at the option of AB Science under certain conditions. They will be repayable in full on the seventh anniversary of the issue date at their nominal value.

Commenting on this announcement, Alain Moussy, Chief Executive Office of AB Science states that: *“The issuance of the Bonds for a total amount of 7.5M Euros provides a level of cash that allows us to pursue our phases 3 and phases 2 clinical development program according to plan. In the current financial environment, the conversion of the Bonds at a price of 12.65 Euros, which is the IPO share price, confirms the confidence of our long term investors.”*

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. AB Science has developed its own portfolio of molecules including masitinib, which has already been registered in veterinary medicine in Europe and in the USA, and is pursuing nine phase 3 studies in human medicine, including six studies on-going in pancreatic cancer, GIST, in metastatic melanoma expressing JM mutation of c-Kit, in mastocytosis, severe persistent asthma, and rheumatoid arthritis.

Further information is available on AB Science’s website: www.ab-science.com

DISCLAIMER

This press release does not constitute an offer to sell or a solicitation of an offer to buy AB Science shares. If you wish to obtain more comprehensive information about AB Science, please refer to documents available on our website www.ab-science.com. This release may contain certain forward-looking statements. Although the Company believes that these statements are based upon reasonable assumptions at the date of publication of this document, they are inherently subject to risks and uncertainties which could cause actual results to differ from the present figures and those expressed or implied in these statements.

Main features of the bond loan

It is a bond loan which, where applicable, is convertible or reimbursable in ordinary shares of the Company, with a nominal amount of seven million five hundred thirty-nine thousand four hundred (7,539,400) euros, divided in hundred forty-nine (149) bonds with nominal value of fifty thousand six hundred (50,600) euros each.

Issue Price

The Bonds will be issued at par, that is for a unit subscription price equal to their nominal value, i.e. fifty thousand six hundred (50,600) euros each, representing a seven million five hundred thirty-nine thousand four hundred (7,539,400) euro bond loan in total.

Annual interests

The Bonds will bear interest at the rate of 1.25% per annum, based on the nominal amount, payable annually on the anniversary of the issue date of the Bonds.

Accrued interests

The Bonds will give right to 4.75% interest per annum, based on the nominal amount, which will not be payable annually on the anniversary of the date of issue but which will be accrued. Accrued interests will be due only in case of reimbursement of the Bonds in cash.

Repayment on maturity

In the absence of conversion or reimbursement in shares, the Bonds will be repaid in full on the seventh anniversary of the date of issue, at their par value. This repayment will be made jointly with the payment of the Accrued interests.

Early redemption

If, before December 31st 2013, the three-month moving average share price of the of the Company is greater or equal to eighteen (18) euros following the communication by the Company of the results of clinical trials or the signature of a pharmaceutical licensing agreement, the Company will have the possibility to reimburse the Bonds in cash by anticipation, as long as the Bondholder had not requested the conversion of the Bonds by means of a notification sent within the 3 business days after the end of the three-month reference period.

Case of conversion

The Bonds are convertible into shares at any time at the initiative of the Bondholder effective on the last business day of the month during which the notification was made, unless the notification was

made less than four business days before that day, in which case the conversion will be effective on the last business day of the following month.

Case of automatic reimbursement

The Bonds are automatically reimbursed in shares, if after December 31st 2013, the three-month moving average share price of the Company with a 1 euro cent nominal value is greater or equal to eighteen (18) euros, effective on the first business day following the last day of the reference three-month period.

Conversion parity or reimbursement

During the conversion or the reimbursement of shares, each Bond will be automatically converted or reimbursed, following the case, in a number "A" of ordinary shares of the Company with a nominal value of 1 euro cent, paid-up by the offset of the bond debt and calculated as follows:

$$A = O / P$$

whereby:

- A: Rounded to nearest integer
- O: Nominal value of the Bonds
- P: 12.65 euros

Capital increase

Conversion of the Bonds will lead to the issue of a maximum of five hundred ninety-six thousand new ordinary shares (596,000) with one (1) euro cent nominal value and twelve euros sixty-four cents (12.64) additional capital. The new shares, issued following the conversion or reimbursement of the Bonds, will be subject to all statutory provisions and assimilated to existing shares.